Heres what Ive learned and heres what the new data say. I have so much respect
This alarming development raises serious red flags about safety, efficacy, and ethical considerations, sounding the alarm for both consumers and healthcare professionals
And with so many GLP-1 medications* available now, things can get a little confusing
According to the results of the new study, this 20% reduction in major adverse events was observed regardless of participants weight at the start of the trial
Tirzepatide is the most direct comparison, operating as a dual GIP/GLP-1 receptor agonist
Take it with a meal that contains some fat for better absorption of fat-soluble vitamins (A, D, E, K)